Gliomas
Efficacy of treating malignant gliomas with sulfasalazine examined
Published in Vaccine Weekly, April 5th, 2006
According to a study from Belgium, "The prognosis of patients suffering from WHO grade 3 and 4 astrocytic glioma remains poor despite surgery, radiation therapy and the use of current chemotherapy regimen. Indeed, the median survival of glioblastoma multiforme (WHO grade 4) patients is at best 14.6 month with only 26.5 percents of the patients still alive after 2 years and the median survival of anaplastic astrocytomas (WHO grade 3) is 19.2 month."
P.A. Robe and colleagues, University of Liege, explained, "Recent evidence suggests that the transcription factor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-04-05)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine
HIV vaccine trial participation barriers among disadvantaged minorities determined - Influenza Vaccines
Influenza virus study demonstrates uneven distribution of MHC class II epitopes - SARS Vaccines
SARS coronavirus vaccine has been developed - Smallpox Vaccines
Vaccinia and smallpox viruses were neutralized by monoclonal antibodies - Vaccine Safety
Sudden infant death syndrome case is linked to hexavalent vaccine - Adenovirus Vaccine
Vaccines elicit CD8+T cell immunity under extreme leukopenia - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
